Drug Profile
Nintedanib - Boehringer Ingelheim
Alternative Names: BIBF-1120; CYNEDIV; Intedanib; OFEV; Ofev; VargatefLatest Information Update: 01 Jan 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Atrium Health; Boehringer Ingelheim; Duke University; European Organisation for Research and Treatment of Cancer; Lurie Cancer Center; M. D. Anderson Cancer Center; National Cancer Institute (USA); Northwestern University; Roswell Park Cancer Institute; University College London; University of Alabama at Birmingham; University of Duisburg-Essen; University of Texas Southwestern Medical Center
- Class Acetamides; Antifibrotics; Antineoplastics; Esters; Indoles; Piperazines; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Lymphocyte specific protein tyrosine kinase p56(lck) inhibitors; Lyn protein-tyrosine kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Src-Family kinase inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Idiopathic pulmonary fibrosis; Interstitial lung diseases; Non-small cell lung cancer; Systemic scleroderma
- Phase III Colorectal cancer; Malignant-mesothelioma; Ovarian cancer; Pulmonary fibrosis
- Phase II Bladder cancer; Breast cancer; Endometrial cancer; Fallopian tube cancer; Gastrointestinal cancer; Inflammatory breast cancer; Liver cancer; Peritoneal cancer; Renal cell carcinoma; Soft tissue sarcoma
- Phase I/II Malignant melanoma; Pancreatic cancer
- No development reported Multiple myeloma; Salivary gland cancer; Solid tumours
- Discontinued Prostate cancer
Most Recent Events
- 10 Nov 2023 Updated efficacy data from the phase III SENSCIS-ON trial in Systemic scleroderma presented at the ACR Convergence 2023 (ACR-ARP-2023)
- 09 Sep 2023 Updated efficacy data from a phase III INBUILD trial in Interstitial lung diseases presented at the 33rd Annual Congress of the European Respiratory Society (ERS-2023)
- 25 Jul 2023 US FDA accepts supplemental new drug application for nintedanib for fibrosing Interstitial lung disease (ILD) (In adolescents, In children) for review